Damora Therapeutics DMRA Institutional Ownership

Updated Oct 28, 2026

Damora Therapeutics, Inc. (NASDAQ:DMRA) was held by 105 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Total holdings of Damora Therapeutics shares rose 15.17% compared with Q1 2026.
• Of the 105 holders, 81 added to their positions, 9 reduced their stakes and 15 left their positions unchanged in Q2 2026.
• Institutional investors held 64.49Mn shares of Damora Therapeutics in total at the end of Q2 2026, up 8.49Mn from the prior quarter and up 64.36Mn from a year earlier.
• FMR LLC led 13F holders of DMRA with 9.23Mn shares as of June 30, 2026.
• The biggest increases in DMRA positions during Q2 2026 came from BlackRock, Inc. (+2.94Mn shares), State Street Corp (+1.36Mn shares), Braidwell LP (+725.53K shares), Geode Capital Management, LLC (+724.24K shares) and UBS Group AG (+679.88K shares).
• Holders that trimmed the most shares of Damora Therapeutics in Q2 2026 while keeping a position were Point72 Asset Management, L.P. (-1.14Mn shares), Bellevue Group AG (-679.15K shares), Cormorant Asset Management, LP (-525K shares), Balyasny Asset Management L.P. (-218.87K shares) and HRT Financial LP (-53.48K shares).
• Business Quant data shows the 10 biggest positions in Damora Therapeutics as of Q2 2026 were held by FMR LLC (9.23Mn shares), Fairmount Funds Management LLC (8.71Mn shares), Avoro Capital Advisors LLC (3.78Mn shares), Venrock Adviser, LLC (3.6Mn shares), BlackRock, Inc. (3.16Mn shares), FCPM III Services B.V. (2.44Mn shares), Ra Capital Management, L.P. (2.4Mn shares), Viking Global Investors LP (2.31Mn shares), Jupiter Topco LLC (2.28Mn shares) and JPMorgan Chase & Co (2.06Mn shares).